KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Efficacy and Safety of ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS-01 Trial.

Juan Wang, Wei Wang, Guanghui Xu, Shushang Liu, Longxing Jiao, Shu Wang, Chaosheng Peng, Yuxuan Ma, Xin Liu, Huade Huo, Haolin Li, Xiaohua Li, Jianjun Yang

MedComm (2020) 7(11) e70958

PMID42984816
PMCIDPMC13732106
DOI10.1002/mco2.70958
发表日期2026-11-05
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

UNLABELLED: This single-center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab-paclitaxel, lobaplatin, and S-1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab-paclitaxel, lobaplatin, and S-1(RNPLS) therapy or nab-paclitaxel, lobaplatin, and S-1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single-center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06169410.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。